News >

Lead FLAURA Researcher Discusses Frontline Osimertinib in EGFR+ NSCLC

Gina Columbus @ginacolumbusonc
Published: Thursday, Sep 28, 2017

Suresh S. Ramalingam, MD

Suresh S. Ramalingam, MD
The much-anticipated progression-free survival (PFS) findings from the phase III FLAURA trial did not disappoint the lung cancer community, as the third-generation EGFR inhibitor osimertinib (Tagrisso) demonstrated a significant improvement in PFS over current first-line therapies for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

during the 2017 ESMO Congress, Ramalingam, deputy director of Winship Cancer Institute of Emory University, discussed the practice-changing FLAURA findings and his thoughts on sequencing should the FDA approve osimertinib in the frontline setting.

OncLive: Please share your insight on the FLAURA findings?

Ramalingam: The FLAURA study was a phase III clinical trial that compared, head to head, osimertinib—a new, third-generation EGFR inhibitor—to standard of care, which are presently used drugs such as erlotinib and gefitinib. Osimertinib is approved in the United States by the FDA for the second-line treatment of EFGR-mutated patients in those who have developed a T790M mutation as a resistance mechanism to the first-generation drug. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication